HOVON 103 Selinexor (FL)

HOVON 103 Selinexor (FL)

A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) in patients aged >66 years

On hold currently

Study treatments


Induction cycle 1
Induction cycle 2
Standard arm
Dauno 60 mg/m² on days 1-3
Cytarabine 200 mg/m² on days 1-7
Cytarabine 1000 mg/m² on days 1-6
Investigational arm
Dauno 60 mg/m² on days 1-3
Cytarabine 200 mg/m² on days 1-7
Selinexor twice weekly from day 1 to day 24
Cytarabine 1000 mg/m² on days 1-6
Selinexor twice weekly from day 1 to day 24


Inclusion criteria


Exclusion criteria


Participating sites

Link